Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016

Jimena Ylescas‐Soria; Alfredo H. de la Torre‐Lujan; Luis A. Herrera; Daniela Miranda; Flavio Grimaldo; Silvia Rivas; Eduardo Cervera; Abelardo Meneses‐García; Fidias E. Leon-Sarmiento; Diddier Prada

doi:10.1002/cam4.2201

Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016

Jimena Ylescas‐Soria, Alfredo H. de la Torre‐Lujan, Luis A. Herrera, Daniela Miranda, Flavio Grimaldo, Silvia Rivas, Eduardo Cervera, Abelardo Meneses‐García, Fidias E. Leon-Sarmiento, Diddier Prada

Baptist Hospital

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cancer Medicine
DOIs	https://doi.org/10.1002/cam4.2201
State	Published - May 2 2019

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1002/cam4.2201License: Unspecified

Cite this

Ylescas‐Soria, J., de la Torre‐Lujan, A. H., Herrera, L. A., Miranda, D., Grimaldo, F., Rivas, S., Cervera, E., Meneses‐García, A., Leon-Sarmiento, F. E., & Prada, D. (2019). Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016. Cancer Medicine. https://doi.org/10.1002/cam4.2201

Ylescas‐Soria, J, de la Torre‐Lujan, AH, Herrera, LA, Miranda, D, Grimaldo, F, Rivas, S, Cervera, E, Meneses‐García, A, Leon-Sarmiento, FE & Prada, D 2019, 'Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016', Cancer Medicine. https://doi.org/10.1002/cam4.2201

@article{bfec5e449f3d478ba01407070ae64a7e,

title = "Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016",

author = "Jimena Ylescas‐Soria and \{de la Torre‐Lujan\}, \{Alfredo H.\} and Herrera, \{Luis A.\} and Daniela Miranda and Flavio Grimaldo and Silvia Rivas and Eduardo Cervera and Abelardo Meneses‐Garc{\'i}a and Leon-Sarmiento, \{Fidias E.\} and Diddier Prada",

year = "2019",

month = may,

day = "2",

doi = "10.1002/cam4.2201",

language = "American English",

journal = "Cancer Medicine",

}

TY - JOUR

T1 - Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016

AU - Ylescas‐Soria, Jimena

AU - de la Torre‐Lujan, Alfredo H.

AU - Herrera, Luis A.

AU - Miranda, Daniela

AU - Grimaldo, Flavio

AU - Rivas, Silvia

AU - Cervera, Eduardo

AU - Meneses‐García, Abelardo

AU - Leon-Sarmiento, Fidias E.

AU - Prada, Diddier

PY - 2019/5/2

Y1 - 2019/5/2

UR - https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcam4.2201

U2 - 10.1002/cam4.2201

DO - 10.1002/cam4.2201

M3 - Article

JO - Cancer Medicine

JF - Cancer Medicine

ER -

Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016

Disciplines

Access to Document

Other files and links

Cite this